tetano
Editor, Senior Moderator
Vet Microbiol. 2017 Mar;201:240-251. doi: 10.1016/j.vetmic.2017.01.020. Epub 2017 Jan 21.
[h=1]Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes.[/h] Chowdhury MY[SUP]1[/SUP], Kim TH[SUP]2[/SUP], Uddin MB[SUP]3[/SUP], Kim JH[SUP]2[/SUP], Hewawaduge CY[SUP]2[/SUP], Ferdowshi Z[SUP]4[/SUP], Sung MH[SUP]5[/SUP], Kim CJ[SUP]6[/SUP], Lee JS[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] To develop a safe and effective mucosal vaccine that broad cross protection against seasonal or emerging influenza A viruses, we generated a mucosal influenza vaccine system combining the highly conserved matrix protein-2 (sM2), fusion peptide of hemagglutinin (HA[SUB]2[/SUB]), the well-known mucosal adjuvant cholera toxin subunit A1 (CTA1) and poly-γ-glutamic acid (γ-PGA)-chitosan nanoparticles (PC NPs), which are safe, natural materials that are able to target the mucosal membrane as a mucosal adjuvant. The mucosal administration of sM2HA2CTA1/PC NPs could induce a high degree of systemic immunity (IgG and IgA) at the site of inoculation as well as at remote locations and also significantly increase the levels of sM2- or HA2-specific cell-mediated immune response. In challenge tests in BALB/c mice with 10 MLD[SUB]50[/SUB] of A/EM/Korea/W149/06(H5N1), A/Puerto Rico/8/34(H1N1), A/Aquatic bird/Korea/W81/2005(H5N2), A/Aquatic bird/Korea/W44/2005 (H7N3) or A/Chicken/Korea/116/2004(H9N2) viruses, the recombinant sM2HA2CTA1/PC NPs provided cross protection against divergent lethal influenza subtypes and also the protection was maintained up to six months after vaccination. Thus, sM2HA2CTA1/PC NPs could be a promising strategy for a universal influenza vaccine.
Copyright ? 2017 Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] Chitosan nanoparticles (PC NPs); Cholera toxin subunit A1 (CTA1); Hemagglutinin fusion peptide (HA2); Influenza vaccine; Matrix protein-2 (sM2); Mucosal immunity; Poly-γ-glutamic acid (γ-PGA)
PMID: 28284616 DOI: 10.1016/j.vetmic.2017.01.020
[h=1]Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes.[/h] Chowdhury MY[SUP]1[/SUP], Kim TH[SUP]2[/SUP], Uddin MB[SUP]3[/SUP], Kim JH[SUP]2[/SUP], Hewawaduge CY[SUP]2[/SUP], Ferdowshi Z[SUP]4[/SUP], Sung MH[SUP]5[/SUP], Kim CJ[SUP]6[/SUP], Lee JS[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] To develop a safe and effective mucosal vaccine that broad cross protection against seasonal or emerging influenza A viruses, we generated a mucosal influenza vaccine system combining the highly conserved matrix protein-2 (sM2), fusion peptide of hemagglutinin (HA[SUB]2[/SUB]), the well-known mucosal adjuvant cholera toxin subunit A1 (CTA1) and poly-γ-glutamic acid (γ-PGA)-chitosan nanoparticles (PC NPs), which are safe, natural materials that are able to target the mucosal membrane as a mucosal adjuvant. The mucosal administration of sM2HA2CTA1/PC NPs could induce a high degree of systemic immunity (IgG and IgA) at the site of inoculation as well as at remote locations and also significantly increase the levels of sM2- or HA2-specific cell-mediated immune response. In challenge tests in BALB/c mice with 10 MLD[SUB]50[/SUB] of A/EM/Korea/W149/06(H5N1), A/Puerto Rico/8/34(H1N1), A/Aquatic bird/Korea/W81/2005(H5N2), A/Aquatic bird/Korea/W44/2005 (H7N3) or A/Chicken/Korea/116/2004(H9N2) viruses, the recombinant sM2HA2CTA1/PC NPs provided cross protection against divergent lethal influenza subtypes and also the protection was maintained up to six months after vaccination. Thus, sM2HA2CTA1/PC NPs could be a promising strategy for a universal influenza vaccine.
Copyright ? 2017 Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] Chitosan nanoparticles (PC NPs); Cholera toxin subunit A1 (CTA1); Hemagglutinin fusion peptide (HA2); Influenza vaccine; Matrix protein-2 (sM2); Mucosal immunity; Poly-γ-glutamic acid (γ-PGA)
PMID: 28284616 DOI: 10.1016/j.vetmic.2017.01.020